Biotech Values

[rfj1862]

ARQT

Anyone here following this as I start to research it?

They seem to have a broad and deep portfolio of dermatology drugs. Roflumilast cream is their first product, approved in psoriasis and likely to be approved for atopic dermatitis and seborrheic dermatitis based on the Phase 3 trial results. So that provides them with revenue to expand their portfolio.

In addition they have 2 *topical* JAK inhibitors for alopecia areata, chronic hand eczema, and vitiligo and they just acquired a biologic but it is preclinical so who knows?

Or is the topical derm space so full of generics that they are never going to make any money?

They have something close to half a billion in the bank so plenty of resources moving forward. So about half their market cap ($1.02B) in cash.